Nasdaq GlobeNewswire

Block X Capital Corp. Announces Completion of Change of Business to Investment Issuer, Change of Name, Change of Management and Resumption of Trading

Del

VANCOUVER, British Columbia, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Block X Capital Corp. ("Block X" or the "Company") (CSE:BXXX) is pleased to announce that further to its press release on December 7, 2017, the Company has completed a change of business from a Mining Issuer to an Investment Issuer and has received approval from the Canadian Securities Exchange to resume trading.

In connection with the change of business, the Company has changed its name to "Block X Capital Corp.".  Trading of the Company's common shares will resume under the new name and under the new ticker symbol "BXXX" at market open on January 24, 2018.

The Company will seek investment opportunities in early-stage to mid-level blockchain and emerging technology companies, and will leverage its extensive network of operators and global thought leaders to provide investors with unparalleled access to investments that are not normally accessible to the average retail investor.

The Company is pleased to announce that it has appointed several notable individuals to form its core management team and board of directors.

  • Darius Eghdami: Chief Executive Officer

    A Chartered Accountant by trade, Darius Eghdami is a serial entrepreneur, investor, and has successfully exited multiple companies. Darius has previously founded and led multiple businesses in digital, data analytics, and the consumer internet. Darius founded FansUnite in 2012, the first social sports book harnessing the power of Blockchain technology. Darius has extensive experience managing companies, raising capital, and developing overall vision and business frameworks. Additionally, Darius was recently named one of Canada's Next 150 Top Entrepreneurs by the TMX Group.
  • Rahim Rajwani: Chief Financial Officer

    Rahim Rajwani brings over 22 years of extensive public and private company experience to Block X Capital. Rahim began his career at Yorkton Securities, and then later moved on to Union Securities where he worked as Chief Compliance Officer and Vice President of Compliance with a primary focus on risk mitigation. Rahim served in successive roles of increasing responsibility at Salman Partners, moving from Chief Compliance Officer, to Vice President, to Managing Director. Rahim aims to bestow his deep expertise in the regulatory, compliance, risk mitigation, and M&A transaction fields in order to support Block X's process of identification, evaluation, and investment in the most promising blockchain and emerging technology companies.  
  • Michele Romanow: Director

    Michele Romanow is a serial entrepreneur who started three companies before her 30th birthday. A "Dragon" on CBC's hit show Dragons' Den, she is a co-founder of Buytopia.ca (acquired by EMERGE Commerce), SnapSaves (acquired by Groupon), and co-founder of Clearbanc, an online financial services platform. She is a Director for Whistler Blackcomb (acquired by Vail Resorts) (NYSE:MTN), Freshii (TSX:FRII), and SHAD Valley. Furthermore, Michele was included in the WXN's "100 Most Powerful Women in Canada", Forbes "Millennial on a Mission" list, and winner of the Toronto Board of Trade Award for entrepreneurs under 30.
  • Cale Moodie: Director

    Cale Moodie is currently Chief Executive Officer & Director of Neptune Dash Technologies (TSX-V:DASH), a builder and operator of Dash Masternodes and exclusive public investor in the Dash digital currency eco-system. He is also a co-founder of Brixton Metals (TSX-V:BBB). Previously, Cale was the Chief Financial Officer of Underworld Resources Inc. until its sale to Kinross Gold in June of 2010. Prior to becoming a successful public market executive of multiple companies, Cale worked for KPMG LLP's Vancouver Industrial Markets Group, with an emphasis on audits for mining and resource-based companies. Cale holds the CPA designation and is a graduate of the University of British Columbia.
  • Zyshan Kaba: Director

    A corporate and securities lawyer by background, Zyshan Kaba is a venture investor and advisor that focuses on financial technology, blockchain, and cryptoassets. With a deep interest in disruptive technology and emerging markets, he focuses on early stage technology companies and his experience covers a variety of areas, including legal counsel, business and regulatory strategy, product development, market research, token sale structuring and analysis, and raising venture capital. Zyshan is also a former executive of a venture backed financial technology company where he was Head of Business and Legal Affairs. Zyshan received his J.D. from the University of Toronto and is called to the bar in Ontario and the state of New York.

Darius Eghdami, CEO, states, "Today marks an incredible milestone for us as the Company has been hard at work surveying the emerging blockchain-enabled industry and is ready to now resume trading, invest its capital, and unlock value in the space. At Block X, we've assembled a world-class team of accomplished investors and pioneers in the emerging technology sector. We look forward to capitalizing on the skill and experience of this executive team we have put together to facilitate investment and create real shareholder value in some of the most promising and disruptive blockchain and emerging technology companies of today and tomorrow."

The Company also announces that Ian Harris, has resigned as director to pursue other opportunities.  The Company thanks Mr. Harris for his dedication to the Company and wishes him all the best in his future endeavors. 

On Behalf of the Company,

Darius Eghdami,  CEO

Tel: 604-628-5616

For Media Contact: 

Natalie Davidson 
natalie@brixmediaco.com 
778 955 8012




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Block X Capital Corp. via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress25.5.2018 07:45Pressemelding

CALGARY, Alberta, May 24, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that on Friday, May 25, 2018, at the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress in Copenhagen, Denmark, the Company is supporting a symposium titled: "Epigenetics in CKD & CVD: A potential breakthrough therapy?" The symposium highlights the role of epigenetics and BET-inhibition in chronic kidney disease and cardiovascular disease, especially in patients with diabetes mellitus, and the significant unmet need that still exists in this patient population. The symposium is co-chaired by Vincent M. Brandenburg, MD - Nephrologist, Aachen, Germany and Kamyar Kalantar-Zadeh, MD - UC Irvine School of Medicine, Irvine, CA, USA, both leading scientists also serving as advisors to Resverlogix's Renal program. The speakers and agenda are as follows: Introduction Vincent M. Brandenburg, MD - University Hospital of the RWTH

Atico Reports Consolidated Financial Results for the First Quarter of 201824.5.2018 22:30Pressemelding

(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, May 24, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the "Company" or "Atico") (TSX.V:ATY) (OTC:ATCMF) today announced its financial results for the three months ended March 31, 2018, posting a net income of $0.4 million. Fernando E. Ganoza, CEO and Director, commented, "The strong production and all-in sustaining cash cost of $1.85 achieved this quarter is not reflected in the financial results as a large concentrate shipment was delayed to the second quarter, along with the revenue associated with those tonnes. The shipping schedule is expected to stabilize during the second quarter, where we will then benefit from the additional shipped concentrate and recognized revenue. We anticipate strong financial results in the next quarter." Mr. Ganoza continued, "Our emphasis will continue to be on further strengthening our balance sheet, improving production costs and most importantly regional

Luxembourg Announced as SNOMED International's Newest Member24.5.2018 15:16Pressemelding

London, United Kingdom, May 24, 2018 (GLOBE NEWSWIRE) -- SNOMED International and Agence eSanté Luxembourg are pleased to announce that Luxembourg has joined the organization as its thirty-second Member. Luxembourg, one of the leading nations in the area of information and communication technology, has set the development of eHealth technologies as a high priority. Agence eSanté, Luxembourg's national agency for the exchange and sharing of medical data, has set an overall mission to facilitate clinical information exchange both within Luxembourg and across other international actors. To work towards this reality, the agency has taken part in discussions about standardization across Europe, a contributing building block achieved with its membership in SNOMED International. With their membership, Agence eSanté has committed their support for the use of structured clinical terminology. When applied to the health sector, interoperability ensures that information systems, and through them h

SEMAFO Signs Underground Mining Services Contract with AUMS24.5.2018 14:00Pressemelding

MONTREAL, May 24, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) reports that it has signed a mining services contract with African Underground Mining Services ("AUMS") to provide turnkey mining services for Siou underground. AUMS is a well-known and reputable mining contractor with underground experience in Burkina Faso and across Africa. Under the mining services contract, AUMS will be responsible for supplying the mining fleet and a skilled labour force for Siou underground in addition to ensuring development, production and auxiliary services. SEMAFO will provide technical services including geology and engineering as well as leveraging the existing surface infrastructure at Mana. The mining services contract has a term of 70 months. The economic terms of the mining services contract are consistent with the economics presented in the Mana pre-feasibility study filed March 29, 2018 on SEDAR. Preparatory work has already commenced on Siou underground with full project deplo

Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors24.5.2018 13:00Pressemelding

- IND Accepted in April by the U.S. FDA for MCLA-158 - UTRECHT, The Netherlands, May 24, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the first patient has been dosed in a Phase 1, first-in human clinical trial of MCLA-158 in patients with solid tumors with an initial focus on metastatic colorectal cancer. The trial will be conducted in Europe, where several Clinical Trial Applications (CTAs) have been approved to date. The Company also announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for MCLA-158, which was accepted by the FDA in April 2018. With this acceptance, Merus plans to open additional sites for this trial in the United States. MCLA-158 is designed to bind to cancer stem cells expressing leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) and epidermal grow

PRA Named International Clinical Research Company of the Year24.5.2018 10:00Pressemelding

RALEIGH, N.C., May 24, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) is pleased to announce it was recognized by PharmaTimes as the International Clinical Research Company of the Year. This is the fifth year in a row that PRA has received this award. "This award celebrates excellence in the clinical research industry and we are honored to once again be recognized by our peers," said Colin Shannon, President and Chief Executive Officer. "This award is possible thanks to the incredibly talented PRA team members we have working around the world who are deeply committed to their work in bringing new and life-saving therapies to the patients who need them." PRA also swept the Clinical Research Associate and Clinical Trial Administrator categories capturing a total of 11 awards. These awards follow PRA's recognition earlier this month in the PharmaTimes Americas competition where PRA also received 11 awards, including Company of the Year. The PharmaTimes, International Cli

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom